Lantern Pharma, Inc., a clinical stage biopharmaceutical company using its proprietary RADR artificial intelligence (AI) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, has entered into a research and development collaboration with TTC Oncology.

The collaboration will focus on leveraging RADR AI insights to advance TTC Oncology’s first- and best-in-class drug candidate TTC-352 for recurrent ER+ breast cancer patients and additional patient populations potentially identified by RADR.

In the U.S., women’s breast cancer remains the most commonly diagnosed cancer, and the second leading cause of cancer related deaths. ER+ breast cancers are estimated to account for 75-80% of all breast cancer cases and can have a recurrence rate between 13% and 41%. Globally, the treatment of ER+ breast cancer is estimated to have a $44 billion market potential by 2027.

Under the terms of the collaboration, Lantern Pharma will receive an exclusive right to license TTC-352, including any collaboration intellectual property (IP), during an exclusive option period. In addition, Lantern and TTC will each participate in upfront, milestone, and royalty payments in the event a third-party licenses IP resulting from the collaboration.

”It is of the utmost importance for cancer drug development to understand targeted tumor biology and mechanisms of resistance in order to select the patient population that will benefit the most from novel therapy,” said Arkadiusz Dudek, TTC Oncology Chief Medical Officer.

“We expect that by using Lantern’s RADR AI platform it can save us time and costs in the further successful clinical development of TTC-352 while providing important information for precision patient selection.”

Panna Sharma, Lantern Pharma’s CEO and President, said: “Using AI insights generated by RADR, we are able to both sharpen existing clinical programs and uncover additional unrealized clinical potential of Lantern’s and our collaborators’ drug candidates. We believe our AI-powered collaboration with TTC Oncology will accelerate the clinical development of TTC-352 for patients with metastatic ER+ breast cancer and will also identify new potential patient populations that can benefit from TTC-352 treatment.”

The collaboration will be powered by RADR’s 25+ billion oncology-focused data points, 200+ advanced ML algorithms, as well as its 4 multi-faceted AI drug discovery and development modules.

The initial goals of the collaboration will be to: identify biomarker or gene signatures to power potential patient selection for an upcoming TTC-352 Phase 2 clinical trial; further characterize TTC-352’s mechanism of action and discover additional treatment indications for TTC-352.